Background: Secondary brain damage after traumatic brain injury (TBI) involves neuroinflammatory mechanisms, mainly dependent on the intracerebral production of specific biomarkers, such as cytokines, neurotrophic factors, and neuron-specific enolase (NSE). NSE is associated with neuronal damage, while neurotrophic factors play a neuroprotective role due to their ability to modulate neuronal precursor biosynthesis, such as doublecortin (DCX). However, the relationships between the expression of these factors and the severity and outcome of TBI are not understood.
Severe traumatic brain injury (TBI) commonly causes impairment of brain functions and extensive neuronal loss. Neuronal cells require the action of some neurotrophic factors, such as nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), and glial derived neurotrophic factor (GDNF), to stimulate growth and differentiation, and to promote recovery of injured brain neurons. 1 TBI induces intracerebral neurotrophic factor biosynthesis, mainly of NGF, by activated neurons, microglia, and astrocytes. 2 Recently, it has been proposed that changes in NGF levels in the CNS might be a neuroprotective response after TBI. 3, 4 In experimental brain injury, exogenous NGF administration prevents or significantly reduces severe neurologic deficits, apoptosis, and brain cell death. 5 Genes and pathways involved in this neuroprotective role remain largely unknown, although recent studies have shown that NGF can influence neurogenesis and neuronal repair. 6 NGF upregulation and intraventricular NGF administration increase the number of new neurons generated in several forebrain structures. 7, 8 Neurogenesis is restricted to limited regions of the hippocampus, such as the subventricular zone (SVZ) and the subgranular zone (SGZ), where stem cells divide to form neuronal precursors, and then migrate into the damaged regions of the brain. 9 Hypoxic-ischemic brain injury and TBI increase the production of new striatum neurons that express doublecortin (DCX). 10 DCX contributes to neuronal repair by stabilizing microtubules in neuronal cells and represents a marker for tracking the migration of new neurons into the injured sites of the brain. 11 An increase of DCX expression was recently demonstrated Scatter plots and estimated linear regression of neurotrophic factors, doublecortin (DCX), and neuron-specific enolase (NSE) concentrations measured in the CSF at T1 with Glasgow Coma Scale (GCS) on admission Nerve growth factor, DCX, and NSE levels correlated significantly with GCS scores. No significant association was found between brain-derived neurotrophic factor and glial-derived neurotrophic factor expression and severity of traumatic brain injury.
following intraventricular BDNF and NGF administration. [12] [13] [14] Nevertheless, the interactions between neurotrophins and DCX in children with TBI and their relationships with the severity of brain injury and clinical outcome are not understood. Conversely, neuron-specific enolase (NSE) is a specific biomarker of neuronal damage. 15 Although raised NSE levels indicate neuronal destruction, its ability to quantify brain injury severity in children with TBI remains controversial. 16 In this study we investigated the expression of NGF, BDNF, GDNF, DCX, and NSE in the CSF of children with TBI, in order to clarify whether these factors can be useful in assessing clinical severity and neurologic outcome and whether these neurotrophins can modulate DCX biosynthesis in the injured brain.
METHODS Population studied. We conducted a prospective observational clinical study in all children with severe TBI (Glasgow Coma Scale [GCS] scores Յ8) consecutively admitted to our pediatric intensive care unit (PICU) and referred within 4 hours from injury. No child with severe TBI was excluded from the study. All patients were treated according to the international guidelines for the management of severe TBI (appendix e-1 on the Neurology ® Web site at www.neurology.org).
To measure NGF, BDNF, GDNF, DCX, and NSE levels at 2 hours (T1) and 48 hours (T2) after admission to the PICU, we collected CSF samples in a closed, sterile system using the same intraventricular catheter set for ICP monitoring. All CSF samples were centrifuged for 10 minutes at 5,000 rpm, and the supernatant was immediately stored at Ϫ70°C until analysis. As controls, we used CSF samples collected from 32 children subjected to lumbar puncture in order to rule out meningitis suspected from clinical and laboratory findings (fever, mental state alteration, and acute phase reactant elevation). None of these patients showed any evidence of meningitis (as confirmed by negative cultures, chemical analysis, and lack of pleocytosis). TBI patients and control subjects were matched for age, sex, and weight. In children with TBI outcomes were assessed 6 months after injury using the Glasgow Outcome Score (GOS), which assigns a score of 1 to children who died, 2 to persistent vegetative state, 3 to severe neurologic deficits, 4 to mild neurologic deficits, and 5 to completely healthy children. Using the GOS, we decided to dichotomize the clinical outcome into two categories: poor outcome when the GOS was between 1 and 3, and good outcome when the GOS was 4 or 5. Although GOS is a global and nonspecific clinical score in infants and children with severe TBI in respect to other more fine disability scales, such as Functional Independence Measures (FIM/WeeFIM), 17, 18 it is widely used in the assessment of late neurologic outcome in childhood morbidity after severe TBI, demonstrating a high sensitivity and specificity from acute injury predictors in this subset of patients. 18, 19 This study was approved by our University Ethical Committee. Parents of all children provided written informed consent. See appendix e-1 for neurotrophic factors, DCX, and NSE assays.
Statistical analysis. Patrizio Pezzotti, Doctor in Statistics at
the Agency for Public Health of Lazio Region, Rome, Italy, conducted the statistical analysis. Mean concentrations of neurotrophic factors, DCX, and NSE measured in the CSF of patients were compared with controls using the Mann-Whitney twotailed test. T1 mean concentrations of neurotrophic factors, DCX, and NSE measured in the CSF of patients were compared with T2 concentrations using the Wilcoxon test. To evaluate the association of neurotrophic factors, DCX, and NSE concentrations with the GCS scores assessed upon admission, we used bidimensional scatter plots on which the estimated linear regression line was superimposed. Spearman correlation was determined and the p value was calculated to evaluate if this was significantly different from zero. To evaluate the association of neurotrophic factors, DCX, and NSE concentrations with GOS assessed at 6 months after TBI, we constructed box plots stratified by class of GOS (GOS Ͻ3 ϭ poor outcome; GOS Ͼ3 ϭ Box plots of neurotrophic factors, doublecortin (DCX), and neuronspecific enolase (NSE) concentrations measured in the CSF at T1 sorted by category of Glasgow Outcome Score
Only nerve growth factor, DCX, and NSE expression was significantly associated with neurologic outcome of children.
good outcome). The choice of dichotomizing GOS was done by convenience given that for some scores there were very few observations (i.e., the score GOS 2 was reported only for one patient Conversely, no significant differences were found in GDNF concentration between patients and controls (p ϭ 0.29). A further increase was noted in the concentrations of NGF, NSE, and DCX in TBI patients at 48 hours postadmission, whereas BDNF and GDNF concentrations decreased from T1 to T2 (figure e-2).
Correlation with severity of TBI. The scatter plots in figure 1 show the linear regression analysis of neurotrophic factors, DCX, and NSE concentrations measured at T1 and GCS scores recorded upon admission to the PICU. NGF, DCX, and NSE concentrations correlated significantly with GCS scores (p Ͻ 0.01) (Spearman correlation ϭ Ϫ0.83, Ϫ0.70, and Ϫ0.90). In contrast, no significant correlation was found between BDNF and GDNF (Spearman correlation ϭ Ϫ0.17; p ϭ 0.36, and Ϫ0.14; p ϭ 0.29) concentrations and GCS scores.
Correlation with outcome. The box plots in figures 2, 3, and 4 illustrate the concentrations of neurotrophic factors, DCX, and NSE in the CSF measured at T1 and T2, as well as their differential (⌬T2 Ϫ T1), sorted by GOS category. NGF, DCX, and NSE concentrations measured at T1 were significantly lower in patients with better neurologic outcomes (p Ͻ 0.01; figure 2 ). However, these patients also had significantly higher NGF (p Ͻ 0.01) and DCX (p Ͻ 0.01) together with lower NSE (p Ͻ 0.01) concentrations measured at T2 ( figure 3) . When evaluating the differentials between T1 and T2 (figure 4), we found that patients with better neurologic outcomes had lower NSE levels (p Ͻ 0.01), but also significantly stronger NGF and DCX upregulation (p Ͻ 0.01). No significant correlation was found between BDNF and GDNF expression and GOS scores. In bivariate ordinal logistic regressions where the outcome was the GOS, the association of CSF concentrations was evaluated adjusting by GCS (table e-2); at time T1, NGF and NSE concentrations were significantly associated with GOS; at time T2, only NSE level was significantly associated with GOS; when considering the change of CSF concentrations between time T1 and T2, NGF, DCX, and NSE changes were significantly associated after having been adjusted by GCS.
Correlation between neurotrophic factor expression and DCX biosynthesis. Figure 5 reports an example of Western blot panels showing the increase of DCX expression in one patient with NGF upregulation from time T1 to time T2. We observed the same DCX behavior in all patients with NGF upregulation, while in other patients and in controls the DCX expression remained at the basal levels (data not shown). To determine the interrelationship between the neurotrophic factor expression and DCX biosynthesis we also evaluated the correlation of their levels in the CSF of patients. Figure e-3 shows the correlation between NGF and BDNF expression and DCX biosynthesis at different time points after TBI. While NGF is significantly associated with DCX biosynthesis both at time T1 and at time T2, the BDNF correlated significantly with DCX only at 48 hours after TBI (time T2). No significant association was found between GDNF expression and DCX biosynthesis (data not shown).
DISCUSSION
This study shows that children with severe TBI develop a marked and early increase in CSF concentrations of NGF, DCX, and NSE with a smaller but significant increase also in BDNF, but not in GDNF levels. Whereas BDNF and GDNF tend to decline, NGF, DCX, and NSE increase further by 48 hours post-trauma, confirming that these molecular markers are involved in the neurobiological response of the brain to injury. The increased levels of NGF, DCX, and NSE soon after head trauma correlated significantly with the severity of neurologic compromise assessed upon admission, while no significant correlation was found between BDNF and GDNF concentrations and GCS scores. Also, and more meaningfully, concurrent strong upregulation of NGF and DCX, relative to low NSE expression soon after injury, seems to predict a better neurologic outcome. The better outcome in this subset of patients might be due to the action of both NGF and BDNF in modulating DCX biosynthesis into the injured brain in the early phases after traumatic insult. Some specific biomarkers of brain injury, such as S100B, myelin basic protein, and NSE have been associated with poorer outcome in children with severe TBI. 20 NSE is an intracellular enzyme detected both in the serum and in the CSF following structural damage of neuronal cells, which appears to be a good marker for the severity of intracranial injury. 21 In our study, the increase in NSE levels was observed soon after brain injury (time T1) and NSE expression was followed by a sustained and delayed peak after 48 hours postinjury (time T2), as previously reported in the literature. 22 This time course of NSE expression in the CSF of TBI patients is characterized by both an early and a late peak, presumably representing two waves of neuronal death, the second of which may represent neuronal apopto- NSE upregulation was significantly associated with poor neurologic outcome (GOS Յ3), whereas nerve growth factor and DCX upregulation was significantly associated with favorable neurologic outcome (GOS Ͼ3) of children with severe traumatic brain injury.
sis. 22 The association between increased NSE expression and poor outcome suggests that the intracerebral production of this biomarker may indicate the extent of neuronal damage in patients with severe TBI. 22 Our results are in keeping with findings showing that NSE upregulation is significantly associated both with the severity of TBI and poorer outcomes of brain injured patients. [23] [24] [25] TBI determines also an increased production of neurotrophic factors in the injured brain soon after traumatic insult. 4, 26 Our results are consistent with the timing of neurotrophic factor expression in the CSF of patients with head trauma, suggesting that this process lies upstream from the complex cascade of neuroreactive mechanisms after TBI. 2, 26, 27 In our patients the expression of NGF, BDNF, and GDNF was differentially modulated, suggesting that these factors might act on different target cells and serve different functions in post-traumatic injury. In particular, NGF upregulation was significantly stronger than the changes in BDNF and GDNF expression and correlated significantly with both clinical severity and neurologic outcomes of patients. However, due to the lack of studies on NGF expression in children with TBI, the specific role of this neurotrophin on the outcome of patients often remains undetected, although NGF exerts a neuroprotective action in brain injured patients. [2] [3] [4] 26 In our study, children with severe TBI showed an early NGF upregulation that reveals a significant correlation both with the severity of head injury and with patient's outcome. Interestingly, patients with a poor outcome (GOS Յ3), mainly children with brain death, showed a flattening of the NGF curve in the CSF and decrease of NGF expression from time T1 to time T2. In contrast, children with a higher GOS had an NGF increase at time T2 and this upregulation shows a significant correlation with a good patient outcome. In these patients, the NGF levels increase strongly and this upregulation appears to be enhanced in the early phases of traumatic injury, in which NGF biosynthesis can be stimulated by activated neurons, microglia, and astrocytes, involved in the intracerebral inflammatory host response after TBI. 28 Cellular brain responses to NGF are elicited through binding and activation of its receptors, TrkA (high affinity receptor) and p75 (low affinity receptor), located in the hippocampus, the SVZ, the SGZ, the nucleus basalis of Meynert, and the cerebral cortex. 29 NGF upregulation in neurotrauma patients may have a beneficial impact on the regenerative capacity of the injured brain via stimulation of TrkA, which influences cellular processes such as proliferation, growth, differentiation, and other cell-specific functions, as well as regeneration. 30 On the other hand, NGF does lead to positive trophic effects, including the nicotinic receptor upregulation in the brain, significantly improving cortical blood flow and counteracting post-traumatic cerebral ischemia and excitotoxicity process, the two primary mechanisms of neuronal death following TBI. 31, 32 Recently, it has also been reported that intraventricular NGF administration improves neuronal survival in infants with hypoxic-ischemic brain injury and the neuroprotective role of NGFtransfected stem cells after experimental TBI. 13, 33, 34 However, little is known about the role of NGF in determining the mechanisms of neuronal repair in the damaged brain. New striatum neurons can generate when neurotrophic factors are infused in the lateral ventricle of the brain and increased levels of intrastriatal neurotrophins promote the initial phase of induced neurogenesis with a considerable increase in the number of DCX-immunoreactive migrating neuroblasts. 12, 13, 35 Our study shows that there is a significant correlation between NGF and BDNF upregulation and DCX expression in the CSF of children with severe TBI and that increased levels of both NGF and DCX correlate significantly with a good outcome for these patients. DCX appears in the CSF soon after traumatic insult, raising the possibility that the release of this marker may have a pivotal role in neuronal connection reorganization after brain injury. From this point of view, DCX can be a useful marker for the assessment of clinical severity and a possible screening tool for the outcome of patients with TBI and other CNS dysfunctions. 14, 36 On the other hand, previous experimental studies have shown that intracerebral neurotrophin administration and transplantation of marrow stromal cells cultured with BDNF and NGF in rats subjected to TBI promote functional recovery by stimulating the biosynthesis of different neuronal markers, such as Neu N, MAP-2, and DCX. 12, 13, 34, 37, 38 DCX-positive cells were present near and among the glial scars early after brain injury migrating from SVZ toward cerebral cortex lesions changing from immature to mature neurons. 39, 40 According to those experimental studies, we observed that the interrelationship between NGF expression and DCX biosynthesis in the CSF of children with TBI increased significantly in the early phase after injury. The correlation between NGF and DCX suggests that both these markers are involved in the neurobiological response of the brain to injury and that NGF, together with BDNF, probably acts by modulating DCX biosynthesis in the brain, reflecting an endogenous attempt against the biochemical cascades triggered by traumatic insult. 14 Limitations of the study. Because of the low sample size and the high correlation with GCS, it remains difficult to understand whether these molecular mechanisms can provide an independent contribution to predict the outcome of children with severe TBI. As a consequence, no multiple regression models including simultaneously all CSF biomarker concentrations together with GCS and their interaction terms were performed to better disentangle the independent effect of these biomarkers with GOS. Moreover, our data may not be generalizable to all children with severe TBI, and to minimize the selection bias of patients clear guidelines for the assessment and treatment must be used. Also, the difficulties with handling and stocking CSF samples and the limitations and difficulties of the techniques used to determine CSF biomarkers may limit the development of this type of study, but defining the relationships between NGF and DCX expression in the injured brain might allow individualization of new strategies for the treatment of TBI patients.
